1. Abraham WT (2000) Blockers. The new standard of therapy for mild heart failure. Arch Intern Med 160:1237–1247
2. Benedict CR (1999) Centrally acting antihypertensive drugs: re-emergence of sympathetic inhibition in the treatment of hypertension. Curr Hypertens Rep 4:305–312
3. Bousquet P, Dontenwill M, Greney H, Feldman J (1998) I x-Imidazoline receptors: an update. J Hypertension 16(suppl 3):S1–S5
4. Broeders MAW, Doevendans PA, Bekkers BCAM, Bronsaer R, van Gorsel E, Heemskerk JWM, oude Egbrink MGA, van Breda E, Reneman RS, van der Zee R (2000) Nebivolol: a third generation β-blocker that augments vascular nitric oxide release. Endothelial β2-adrenergic receptor-mediated nitric oxide production. Circulation 102:677–684
5. Brown MJ (1995) To beta block or better block? β1-selectivity rarely matters in clinical practice despite the hype. Br Med J 311:701–702